NanoViricides Inc. Files Quarterly Report, Reports Fiscal Position Strengthened by Subsequent Raise

NanoViricides has filed its quarterly report, highlighting the potential of its clinical-stage drug NV-387 to address unmet medical needs in viral diseases. NV-387 has a novel mechanism of action and nanomedicine technology, mimicking host attachment receptors to evade viral escape. It has the potential to address major shortcomings in approved drugs for Influenza, RSV, Measles, MPox, and Smallpox. The company's fiscal position has been fortified by a recent raise.